

## CORPORATE PROFILE


AXIM Biotechnologies is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products as well as alternative sources of energy. We prioritize the well-being of our customers while embracing a solid fiscal strategy. We believe to be setting the green standard for cannabinoid bioscience through the discovery and commercialization of new materials and technologies for healthy living, all while respecting the environment.

5 Rockefeller Plaza  
20th Floor  
New York, NY 10111  
Phone: (212) 751-0001  
<http://www.aximbiotech.com>  
[Info@aximbiotech.com](mailto:Info@aximbiotech.com)

Grayling  
101 Avenue of the Americas  
8th Floor  
New York, NY 10013  
(646) 284 9474  
[shiwei.yin@grayling.com](mailto:shiwei.yin@grayling.com)  
[lucia.domville@grayling.com](mailto:lucia.domville@grayling.com)

## STOCK PERFORMANCE

Symbol	AXIM
Exchange	OTCQB
Market Cap.	349.59m
52 Week Range	4.45 - 19.80
Close	6.45
Volume	13
Shares Outstanding	52,569,441
As of Nov 17, 2017 4:00 pm	



## MANAGEMENT TEAM

**Dr. George E. Anastassov** – Chief Executive Officer

**Dr. Philip. A. Van Damme** – Chief Scientific/Medical Officer

**Lekhram Changoer** – Chief Technology Officer

## RECENT HEADLINES

[Nov 7, 2017 - Biotech M&A Momentum Attractive for Cannabinoid R&D Space](#)

[Oct 30, 2017 - Therapix Initiates Non-Clinical Studies for its THC Antibacterial Treatment](#)

[Oct 25, 2017 - Biotechs Develop Proprietary Systems to Drive CBD Research and Development](#)

[Oct 25, 2017 - AXIM Targets Cannabinoid-based Ophthalmic Solutions -- SECFilings.com](#)

[Oct 19, 2017 - 5 of Today's Biggest Marijuana Stock Losers - Thursday, October 19th](#)